Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock
The offering will be made only by means of a prospectus, copies of which may be obtained by contacting
A registration statement relating to these securities has been filed with the
Revance is a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and therapeutic indications. Revance has developed a platform technology, TransMTS®, which enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.
Certain of the statements made in this press release are forward looking, such as those, among others, relating to Revance's expectations regarding the completion of the public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not Revance will be able to raise capital through the sale of shares of common stock, the final terms of the public offering, market and other conditions, the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in
Westwicke Partners, Investor Relations Lynn Pieper415-202-5678 firstname.lastname@example.org
News Provided by Acquire Media